Reduced Tablet Size for "EsoDuo S"

Improved Dosing Convenience for Patients Requiring Long-Term Medication

On June 2, Chong Kun Dang announced the launch of "EsoDuo Mini," a reduced-size formulation of its gastroesophageal reflux disease (GERD) treatment "EsoDuo S."


EsoDuo Mini is designed to alleviate the physical discomfort that GERD patients—who frequently need long-term medication due to recurrent symptoms—often experience when swallowing pills. By significantly reducing the tablet size, the product aims to improve dosing convenience.

Chong Kun Dang Launches "EsoDuo Mini" for Gastroesophageal Reflux Disease Treatment View original image

This product has demonstrated pharmaceutical equivalence to EsoDuo S 20/700 mg. In addition, the amounts of esomeprazole, the main ingredient in EsoDuo S, and sodium bicarbonate have both been halved to enhance medication adherence.


A representative from Chong Kun Dang stated, "EsoDuo Mini meets the key needs in the GERD treatment market—'rapid symptom relief' and 'improved dosing convenience.' By strengthening the EsoDuo brand lineup, we aim to maximize synergy with existing products and further expand our presence in the gastrointestinal therapeutics market."



Chong Kun Dang's "EsoDuo" is a combination drug consisting of esomeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid. It maintains esomeprazole's acid-suppressing effect while delivering a faster onset of action compared to monotherapy. The mechanism involves sodium bicarbonate rapidly increasing the gastric pH, which prevents esomeprazole from breaking down in the acidic environment. As a result, the drug reaches its peak blood concentration within 30 minutes of administration, providing rapid relief of GERD symptoms.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing